Lymphoedema Evidence Library › Topics › Lymphatic surgery
Lymphatic surgery
Lymphatic surgery
58 sources
Evidence in one minute
- The evidence base is mostly level 4–5: of the 50 most-cited lymphatic surgery papers, 74% are level 4–5 and only two are RCTs. Al Qurashi AA 2026
- Choose by pathology: fluid-dominant (pitting) → physiological surgery (LVA, VLNT); fat/fibrosis-dominant (non-pitting) → reductive surgery (liposuction, excision). Zurbuchen 2025 · Executive Committee of the International Society of Lymphology 2023
- LVA: works where functional lymphatics are seen on ICG; complication rate ~1%; in BCRL the multicentre N-LVA RCT's primary outcome was null at 6 months (low certainty; revised 2026-10-08). Lee 2025 · Gaxiola-García 2024
- Lower limb (umbrella review): volume −34% to −47% (very low certainty); cellulitis −2.1 episodes/year after VLNT and 0.84→0.07/year after LVA (low by GRADE — uncontrolled before-after; the review's guideline scale calls it moderate; revised 2026-10-08); ILR prevents ~30 per 100 cases after iliofemoral lymphadenectomy but may worsen oncological outcome in limb skin cancers. Gloviczki 2026
- VLNT: better for advanced disease; donor-site lymphoedema is the main risk; combined with radical reduction in stage III (series). Perets 2024 · Ciudad 2019
- Liposuction: largest, most consistent volume reduction for non-pitting fat-dominant disease (82% weighted average in early series) only with lifelong flat-knit compression. International Lymphoedema Framework 2012
- Excisional (Charles, Thompson): complication rate ~46%; ISL says avoid except for elephantiasis/genital disease. Executive Committee of the International Society of Lymphology 2023
- Every review agrees: surgery does not end compression or self-care. Flores 2024
- Technique notes: Zheng 2024; ICG mapping in SA journal context: Hsu 2025.
Appraisal update 2026-10-09
- Narrative reviews over-read the trials. Lee 2025 calls the null N-LVA interim “significant proof” of benefit; Perets 2024 claims VLNT is “most cost-effective” with no cost data and misreports the Dionyssiou RCT; Park 2020 and Zurbuchen 2025 quote uncontrolled percentage reductions without design caveats. Use the RCT pages and Gloviczki 2026 for effects. Lee 2025 · Perets 2024 · Park 2020 · Zurbuchen 2025
- Technique and case series: Zheng 2024 OLA (10 patients; text age and BMI do not match its table; 7-day patency only) and Ciudad 2019 — very low certainty. The Al Qurashi audit counts the van Mulken robotic pilot as one of only two “level 2” RCTs; it compared two ways of doing LVA, not LVA v no LVA. Zheng 2024 · Al Qurashi AA 2026
- Cochrane protocol (Haas 2025) is methodologically strong; declared interests include a compression-garment consultancy and a 3M advisory board. Haas 2025
For a vascular surgeon in South Africa
LVA needs supermicrosurgery and ICG imaging (limited availability in SA — LAOSA 2018 notes not all procedures are offered). Liposuction for fat-dominant disease and ILR at the time of groin/pelvic node dissection are the most relevant to vascular and surgical oncology practice. Do not cite the anonymous "clinical guide" (Unknown unknown).
Textbooks
Cheng 2016 · Harder 2024 · Schaverien 2022 · Baumeister 2017
Update 2026-10-08 — downloaded evidence
- Randomised evidence now held (graded 2026-10-08): N-LVA (LVA v CDT, early BCRL): primary HRQoL outcome null, physical-function domain better (below MCID), volume unchanged at 6 months — low certainty; not cost-effective from a health-service perspective (moderate). ILR at axillary dissection: volume-defined BCRL 9.5% v 32% (preliminary, low certainty). Cochrane review of microsurgery vs CDT under way (protocol). Jonis 2024 · Kleeven 2026 · Coriddi 2023 · Haas 2025
Update 2026-10-09 — open-access batch 1 (2020–2026 trials and reviews)
- LVA v CDT for cellulitis (Mihara 2024 RCT): LVA added to decongestive therapy cut cellulitis by 0.35 episodes per 6 months (−0.62 to −0.09), but 111 of 336 randomised were excluded and 69 refused their arm — very low certainty; no effect on circumference or pain. This is the "RCT of over 300 cases" cited by Zurbuchen (verified 2026-10-09). Mihara 2024
- Liposuction meta-analysis (Chen 2025): ~92% excess-volume reduction pooled from case series only, with internally inconsistent counts and overlapping Malmö cohorts — very low; use the original series and ILF 2012 instead. Chen 2025
- Axillary reverse mapping with selective dissection (Gennaro 2022 RCT): measured BCRL at 1 year 21% v 42% with standard dissection — low certainty; no difference in patients' own ratings. Gennaro 2022
Update 2026-10-09 — open-access batch 2
- Microsurgery pooled series (Meuli 2023, 150 studies, 6496 patients): excess circumference −36%, volume −33% (prediction interval +6% to −71%), cellulitis −1.9 episodes/year — very low (single-arm). Meuli 2023
- Leg VLNT (Shah 2026, 25 retrospective series): ~25% circumference/volume reduction, cellulitis −1.9/year, complications ~16% (venous congestion 7%) — very low; internal count errors and probable duplicate data; the donor-site ranking is not evidence. Shah 2026
Update 2026-10-09 — figures checked in the original PDFs
- LVA and cellulitis (Mihara 2024): the LVA arm started with almost twice the cellulitis rate of the control arm, so part of its larger fall is regression to the mean — stays very low. Liposuction infections (Chen 2025): the pooled estimate cannot be traced to its two source studies. Mihara 2024 · Chen 2025
Update 2026-10-09 — open-access batch 3
- ICG-targeted drainage after LVA (Wang 2026, China) — better patency and circumference in an unblinded, retrospectively registered trial — very low. Wang 2026
Update 2026-10-09 — open-access batch 6
- Node-sparing at pelvic lymphadenectomy: preserving circumflex iliac nodes reduced leg lymphoedema (low). Wang 2024
- Stem-cell (ADRC) lipotransfer to the axilla: the Danish placebo-controlled trial found no benefit; responder analysis found no cell-related signal. Authors advise against its use. Andersen 2024
Update 2026-10-09 — open-access batch 7
- Robotic LVA (MUSA, van Mulken 2020 pilot): feasible but slower and lower-scoring anastomoses than manual; developers are company shareholders. van Mulken TJM 2020
Update 2026-10-09 — open-access batch 8 (reviews)
- Immediate lymphatic reconstruction (Cook 2022 review): 6.6% lymphoedema after ILR, but the 30.5% comparison comes from 17 patients in whom ILR was abandoned — very low; prefer the Coriddi RCT. Cook 2022
Update 2026-10-09 — open-access batch 9 (reviews)
- Immediate lymphatic reconstruction (Li 2025, 17 studies): RR 0.41 (NNT 9) for early BCRL, but 8 single-arm studies were compared with a borrowed literature rate and the benefit was no longer significant after 3 years — low (early), very low (lasting). Li 2025
- Microsurgery outcomes (Zurfluh 2025, 74 series): pre–post QoL gains (SMD 0.86) without controls — very low. Omental transfer (Jarvis 2021): case series only. Cell therapy (Lafuente 2021): mainly animal data. Zurfluh 2025 · Jarvis 2021 · Lafuente 2021
Update 2026-10-09 — open-access batch 10 (reviews)
- Immediate LVA across cancers (Hinson 2025): 7.1% v 35.0%, RR 0.31, mostly non-randomised — low; QoL benefit of ILR not shown (Kumar 2026, SMD 0.77, −1.17 to 2.70). Hinson 2025 · Kumar 2026
- VLNT for BCRL (Winters 2022): ~40% reduction in volume difference in case series; donor complications 12% — very low. Kong 2022: reoperation 26%, lymph leakage 32% reported alongside an OR of 7 for "excellent" results. Winters 2022 · Kong 2022
- Other reviews: leg PROMs (Grünherz 2021), MRL planning (Forte 2021), narrative (Gasteratos 2021). Grünherz 2021 · Forte 2021 · Gasteratos 2021
Update 2026-10-09 — open-access batch 12 (reviews; final)
- Expected benefit (Hahn 2025, 52 studies): about one-third improvement in arm (36%) and leg (34%) lymphoedema after LVA or VLNT, from case series — very low. Robotic periorbital LVA: case report (Imholz 2025). Hahn 2025 · Imholz 2025
How the evidence points
| High | Mod. | Low | V. low | None | |
|---|---|---|---|---|---|
| Positive | 0 | 0 | 5 | 3 | 0 |
| Null or negative | 0 | 0 | 2 | 0 | 0 |
Sources on this page with a comparison, by the result of their primary outcome and the GRADE certainty of their main finding (Mod. = Moderate, V. low = Very low, None = not graded). Context sources are not counted. How direction is decided.
All 58 sources
Loading 58 sources…